Class patent landscape
Atypical Antipsychotic
Cross-drug patent estate across 14 approved drugs in the atypical antipsychotic class. Loss-of-exclusivity timeline, sponsor concentration, and per-drug links to full patent landscapes.
Approved drugs
14
with patent data
OB patents
103
across the class
Patent families
40
1,421 docs · 55 countries
Earliest US LOE
Mar 1, 2027
first drug off patent
Latest US LOE
Mar 16, 2042
last drug off patent
Loss-of-exclusivity waterfall
Drugs in the atypical antipsychotic class sorted by US Orange Book expiry — earliest LOE first. Each row links to the drug's full patent landscape.
| Drug | Sponsor | OB patents | Families | Intl docs | Latest US expiry | |
|---|---|---|---|---|---|---|
| ABILIFY aripiprazole | OTSUKA | 2 | 2 | 68 | Mar 1, 2027 +1y | View → |
| PERSERIS KIT risperidone | INDIVIOR | 10 | 2 | 75 | Feb 12, 2028 +2y | View → |
| VERSACLOZ clozapine | DOUGLAS PHARMS | 1 | 1 | 13 | Apr 30, 2028 +2y | View → |
| VRAYLAR cariprazine hydrochloride | AbbVie | 5 | 3 | 165 | Sep 16, 2029 +3y | View → |
| FANAPT iloperidone | VANDA PHARMS INC | 8 | 7 | 112 | Dec 27, 2031 +5y | View → |
| RYKINDO risperidone | SHANDONG LUYE | 5 | 1 | 57 | Apr 9, 2032 +6y | View → |
| REXULTI brexpiprazole | OTSUKA | 11 | 2 | 131 | Apr 11, 2033 +7y | View → |
| ABILIFY ASIMTUFII aripiprazole | OTSUKA | 4 | 1 | 105 | Apr 22, 2033 +7y | View → |
| SECUADO asenapine | HISAMITSU | 6 | 3 | 65 | Sep 21, 2033 +7y | View → |
| ABILIFY MAINTENA KIT aripiprazole | OTSUKA PHARM CO LTD | 6 | 2 | 72 | Apr 5, 2034 +8y | View → |
| CAPLYTA lumateperone tosylate | INTRA-CELLULAR | 23 | 8 | 310 | Dec 9, 2040 +14y | View → |
| LYBALVI olanzapine | ALKERMES INC | 14 | 3 | 111 | Nov 11, 2041 +15y | View → |
| OPIPZA aripiprazole | XIAMEN LP PHARM CO | 2 | 1 | 6 | Dec 14, 2041 +15y | View → |
| UZEDY risperidone | Teva | 6 | 4 | 131 | Mar 16, 2042 +16y | View → |
Sponsor concentration
Which companies anchor the IP across this class.
Pro Sponsor concentration — Which sponsors anchor the IP across the class
See what Pro includes ↓ Methodology & data sources
- Drugs in class: aggregated from
drug.pharmClassEpcfield. Drugs without EPC tags are not included here (data gap, not coverage limitation). - Patent data: per-drug patent thickets from FDA Orange Book / Purple Book + BigQuery family expansion. See individual drug patent pages for source detail.
- LOE waterfall: sorted by
latestPatentExpiryfrom Orange Book. Reflects US patent term adjustments (PTA) but not exclusivity overlays (ODE, NPP, PED). - Class-level analysis: sums across per-drug thickets. Same patent family may appear in multiple drugs (e.g., Jakafi + Opzelura share composition family) — counted once per family per drug for OB totals.
Intelligence, not legal advice. Class-level summary reflects what's listed publicly. Generic launch dynamics depend on per-drug NCE/ODE/PED overlays, ANDA Para IV outcomes, and BPCIA settlements not captured here.
TheraRadar Pro — patent intelligence
Free covers what's publicly listed: Orange Book patents, basic stats, composition expiry. Pro adds the deeper view: LLM-driven estate analysis, full international family thicket, and (coming soon) alerts + exports.
Always free
- • Orange Book patent table (every patent, family, use code, expiry)
- • Stat strip — OB count, families, global doc footprint, multiplier
- • Composition family priority + nominal global expiry
- • International vs US expiry comparison
- • Coverage status + methodology
- • LOE waterfall across all approved drugs in the class
PRO
What Pro adds today
- Estate analysis (sections 2-5) — Composition anchor, lifecycle layers, international vs US, strategic outlook
- Full patent families table — Country lists, doc counts, priority dates per family
- Sponsor concentration — Who owns the IP across the class
- International nominal expiries — Priority + 20 years per family with global vs US gap
$99/year. Cancel anytime. Single sign-on via Google.
Class patent data updated: Jun 17, 2026